1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer 4.2.2 Chronic Nature of Diseases Leads to Consistent Demand for Drugs 4.2.3 Advancements in Molecular Biology, Development of Drugs, and Diagnostic Technology 4.2.4 Emphasis on Early Diagnosis 4.3 Market Restraints 4.3.1 Drug Toxicity and Side Effects 4.3.2 Drugs Losing Patent Exclusivity 4.3.3 High Costs Associated with Diagnosis and Treatments 4.3.4 Stringent Regularly Guidelines 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry 5 MARKET SEGMENTATION 5.1 By Therapeutics 5.1.1 Targeted Therapies 5.1.2 Chemotherapy 5.1.3 Surgery 5.1.4 Other Therapeutics 5.2 Diagnostics 5.2.1 Imaging 5.2.2 Biopsy 5.2.3 Endoscopy 5.2.4 Other Diagnostics 5.3 Geography 5.3.1 North America 5.3.1.1 US 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 UK 5.3.2.2 Germany 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Apex Medical Corp. 6.1.2 Chart Industries Inc. 6.1.3 Devilbiss Healthcare LLC 6.1.4 Fisher & Paykel 6.1.5 GE Healthcare 6.1.6 Intersurgical Ltd 6.1.7 Invacare Corporation 6.1.8 Medtronic PLC 6.1.9 Philips Healthcare 6.1.10 ResMed 7 MARKET OPPORTUNITIES AND FUTURE TRENDS